Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1912 2
1947 1
1952 1
1953 1
1955 1
1956 1
1958 1
1959 3
1963 3
1977 2
1978 1
1979 3
1981 4
1983 4
1984 5
1985 4
1986 6
1987 4
1988 2
1989 7
1990 8
1991 5
1992 4
1993 9
1994 7
1995 11
1996 9
1997 3
1998 5
1999 10
2000 3
2001 6
2002 15
2003 7
2004 7
2005 11
2006 14
2007 8
2008 8
2009 11
2010 19
2011 13
2012 14
2013 27
2014 24
2015 14
2016 20
2017 40
2018 33
2019 29
2020 28
2021 49
2022 51
2023 55
2024 34
2025 57
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

663 results

Results by year

Filters applied: . Clear all
Page 1
Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
Zhou C, Li X, Wang C, Zhang J. Zhou C, et al. Clin Rev Allergy Immunol. 2021 Dec;61(3):403-423. doi: 10.1007/s12016-021-08883-0. Epub 2021 Aug 17. Clin Rev Allergy Immunol. 2021. PMID: 34403083 Review.
There are several clinical treatments for AA, varying from one or multiple well-defined patches to more diffuse or total hair loss of the scalp (alopecia totalis) or hair loss of the entire body (alopecia universalis). The available treatments for AA, such as cortic …
There are several clinical treatments for AA, varying from one or multiple well-defined patches to more diffuse or total hair loss of the sc …
Janus kinase inhibitors for alopecia areata.
King BA, Craiglow BG. King BA, et al. J Am Acad Dermatol. 2023 Aug;89(2S):S29-S32. doi: 10.1016/j.jaad.2023.05.049. J Am Acad Dermatol. 2023. PMID: 37591562 Review.
Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis.
Lee HH, Gwillim E, Patel KR, Hua T, Rastogi S, Ibler E, Silverberg JI. Lee HH, et al. J Am Acad Dermatol. 2020 Mar;82(3):675-682. doi: 10.1016/j.jaad.2019.08.032. Epub 2019 Aug 19. J Am Acad Dermatol. 2020. PMID: 31437543
OBJECTIVE: To determine the prevalence, incidence, and predictors of AA, alopecia totalis, alopecia ophiasis, and alopecia universalis. METHODS: A systematic review of all published cohort and cross-sectional studies that analyzed AA and its subtypes. ...
OBJECTIVE: To determine the prevalence, incidence, and predictors of AA, alopecia totalis, alopecia ophiasis, and alopecia univers …
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis.
Mesinkovska N, King B, Zhang X, Guttman-Yassky E, Magnolo N, Sinclair R, Mizuashi M, Shapiro J, Peeva E, Banerjee A, Takiya L, Cox LA, Wajsbrot D, Kerkmann U, Law E, Wolk R, Schaefer G. Mesinkovska N, et al. J Dermatol. 2024 Nov;51(11):1414-1424. doi: 10.1111/1346-8138.17442. Epub 2024 Sep 27. J Dermatol. 2024. PMID: 39328096 Free article. Clinical Trial.
This post-hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) evaluated the efficacy and safety of ritlecitinib, an oral Janus kinase 3/TEC family kinase inhibitor, in patients with alopecia totalis (AT) and alopecia universalis (AU). Patients aged 12 years w …
This post-hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) evaluated the efficacy and safety of ritlecitinib, an oral Janus kinase …
Treatments for alopecia areata: a network meta-analysis.
Mateos-Haro M, Novoa-Candia M, Sánchez Vanegas G, Correa-Pérez A, Gaetano Gil A, Fernández-García S, Ortega-Quijano D, Urueña Rodriguez MG, Saceda-Corralo D, Bennouna-Dalero T, Giraldo L, Tomlinson J, Vaño-Galván S, Zamora J. Mateos-Haro M, et al. Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD013719. doi: 10.1002/14651858.CD013719.pub2. Cochrane Database Syst Rev. 2023. PMID: 37870096 Free PMC article.
OBJECTIVES: To assess the benefits and harms of the treatments for alopecia areata (AA), alopecia totalis (AT), and alopecia universalis (AU) in children and adults. SEARCH METHODS: The Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, ClinicalTrials.gov …
OBJECTIVES: To assess the benefits and harms of the treatments for alopecia areata (AA), alopecia totalis (AT), and alopecia unive …
Pediatric Alopecia Areata.
Afford R, Leung AKC, Lam JM. Afford R, et al. Curr Pediatr Rev. 2021;17(1):45-54. doi: 10.2174/1573396316666200430084825. Curr Pediatr Rev. 2021. PMID: 32351186 Review.
Other clinical variants include alopecia totalis, alopecia universalis, ophiasis, sisaipho, and Canitis subita. There are multiple treatment options for AA, including conservative treatment, and topical, oral, and injectable medications. ...
Other clinical variants include alopecia totalis, alopecia universalis, ophiasis, sisaipho, and Canitis subita. There are mult …
Alopecia Universalis: Never Give Up?
Jiminez V, Riess A, Mayo T, Elewski B. Jiminez V, et al. J Drugs Dermatol. 2025 Mar 1;24(3):316-318. doi: 10.36849/JDD.8587. J Drugs Dermatol. 2025. PMID: 40043270
CASE PRESENTATION: We present the case of a 28-year-old female with alopecia universalis and a Severity of Alopecia Tool (SALT) of 100%, who failed 1 year of baricitinib therapy and was switched to ritlecitinib. ...
CASE PRESENTATION: We present the case of a 28-year-old female with alopecia universalis and a Severity of Alopecia Tool (SALT …
663 results